Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors.

Authors :: Tani R
Matsunaga K
Toda Y
Inoue T
Fu HY
Minamino T
Source :: Clinical case reports [Clin Case Rep] 2024 Feb 19; Vol. 12 (2), pp. e8537. Date of Electronic Publication: 2024 Feb 19 (Print Publication: 2024).
Publication Year :: 2024
Abstract: Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment strategies.<br />Competing Interests: None to declare.<br /> (© 2024 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)

Full Text Access

Tools